Logo image of ASMB

ASSEMBLY BIOSCIENCES INC (ASMB) Stock Fundamental Analysis

NASDAQ:ASMB - Nasdaq - US0453962070 - Common Stock - Currency: USD

14.2  +0.44 (+3.2%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ASMB. ASMB was compared to 560 industry peers in the Biotechnology industry. ASMB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASMB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ASMB has reported negative net income.
In the past year ASMB has reported a negative cash flow from operations.
ASMB had negative earnings in each of the past 5 years.
ASMB had negative operating cash flow in 4 of the past 5 years.
ASMB Yearly Net Income VS EBIT VS OCF VS FCFASMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With a decent Return On Assets value of -33.71%, ASMB is doing good in the industry, outperforming 62.32% of the companies in the same industry.
The Return On Equity of ASMB (-120.44%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -33.71%
ROE -120.44%
ROIC N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ASMB Yearly ROA, ROE, ROICASMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

ASMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASMB Yearly Profit, Operating, Gross MarginsASMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASMB has more shares outstanding
Compared to 5 years ago, ASMB has more shares outstanding
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASMB Yearly Shares OutstandingASMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ASMB Yearly Total Debt VS Total AssetsASMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ASMB has an Altman-Z score of -9.30. This is a bad value and indicates that ASMB is not financially healthy and even has some risk of bankruptcy.
ASMB has a Altman-Z score of -9.30. This is in the lower half of the industry: ASMB underperforms 71.79% of its industry peers.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.3
ROIC/WACCN/A
WACC9.52%
ASMB Yearly LT Debt VS Equity VS FCFASMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ASMB has a Current Ratio of 2.42. This indicates that ASMB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.42, ASMB is not doing good in the industry: 70.54% of the companies in the same industry are doing better.
A Quick Ratio of 2.42 indicates that ASMB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.42, ASMB is doing worse than 68.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.42
ASMB Yearly Current Assets VS Current LiabilitesASMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

ASMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.79%, which is quite impressive.
ASMB shows a strong growth in Revenue. In the last year, the Revenue has grown by 298.16%.
ASMB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.31% yearly.
EPS 1Y (TTM)42.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.52%
Revenue 1Y (TTM)298.16%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%62.82%

3.2 Future

ASMB is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.37% yearly.
The Revenue is expected to grow by 6.92% on average over the next years.
EPS Next Y13.79%
EPS Next 2Y6.99%
EPS Next 3Y7.53%
EPS Next 5Y-3.37%
Revenue Next Year39.57%
Revenue Next 2Y5.15%
Revenue Next 3Y30.3%
Revenue Next 5Y6.92%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ASMB Yearly Revenue VS EstimatesASMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ASMB Yearly EPS VS EstimatesASMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ASMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASMB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASMB Price Earnings VS Forward Price EarningsASMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASMB Per share dataASMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.99%
EPS Next 3Y7.53%

More info and screens

0

5. Dividend

5.1 Amount

ASMB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (5/29/2025, 8:00:00 PM)

14.2

+0.44 (+3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners50.36%
Inst Owner Change-1.05%
Ins Owners12.08%
Ins Owner Change10.73%
Market Cap108.49M
Analysts82.22
Price Target34.68 (144.23%)
Short Float %0.19%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.63%
Min EPS beat(2)24.55%
Max EPS beat(2)26.71%
EPS beat(4)4
Avg EPS beat(4)28.46%
Min EPS beat(4)12.95%
Max EPS beat(4)49.61%
EPS beat(8)5
Avg EPS beat(8)14.4%
EPS beat(12)6
Avg EPS beat(12)9.04%
EPS beat(16)10
Avg EPS beat(16)11.89%
Revenue beat(2)1
Avg Revenue beat(2)8.39%
Min Revenue beat(2)-22.37%
Max Revenue beat(2)39.15%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.6%
EPS NY rev (1m)0%
EPS NY rev (3m)25.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.95%
Revenue NY rev (1m)20.89%
Revenue NY rev (3m)69.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.8
P/FCF N/A
P/OCF N/A
P/B 3.25
P/tB 3.25
EV/EBITDA N/A
EPS(TTM)-6.23
EYN/A
EPS(NY)-5.75
Fwd EYN/A
FCF(TTM)-6.69
FCFYN/A
OCF(TTM)-6.69
OCFYN/A
SpS3.73
BVpS4.37
TBVpS4.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.71%
ROE -120.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.71%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.42
Altman-Z -9.3
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)32.95%
Cap/Depr(5y)216.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.52%
EPS Next Y13.79%
EPS Next 2Y6.99%
EPS Next 3Y7.53%
EPS Next 5Y-3.37%
Revenue 1Y (TTM)298.16%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%62.82%
Revenue Next Year39.57%
Revenue Next 2Y5.15%
Revenue Next 3Y30.3%
Revenue Next 5Y6.92%
EBIT growth 1Y29.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.57%
EBIT Next 3Y40.7%
EBIT Next 5Y2.97%
FCF growth 1Y-327.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-324.76%
OCF growth 3YN/A
OCF growth 5YN/A